#4 Leadership Chat: Francois Nader - A Few Things - 42 Min

We discussed a number of things including: 1. How to lead in a time of great uncertainty 2. Raising funds and managing teams during a downturn 3. What he's seeing in biotech and biopharma sectors Francois Nader, MD, is a leading value builder in the biopharma industry. Dr. Nader currently serves as chairman of Acceleron Pharma (XLRN), Prevail Therapeutics (PRVL) and Talaris Therapeutics; and board director of Alexion Pharmaceuticals (ALXN) and Moderna (MRNA). Previously, Dr. Nader was President, Chief Executive Officer and Executive Director of NPS Pharma from 2008 to 2015. During his tenure as CEO, Dr. Nader transformed NPS Pharma into a leading global biotechnology company focused on delivering innovative therapies to patients with rare diseases. The company was acquired by Shire for $5.2B in 2015. Dr. Nader won the Ernst and Young National Life Science Entrepreneur of the Year® award in 2013. Before NPS, Dr. Nader was a venture partner at Care Capital. Prior, he served on the North America Leadership Team of Aventis and its predecessor companies holding a number of executive positions including senior vice-president, integrated healthcare markets and North America medical and regulatory affairs. Previously, he led the global commercial operations at the Pasteur Vaccins’ division of Rhone-Poulenc. Dr. Nader is past chairman of BioNJ, New Jersey’s biotechnology trade organization and has served on the board of the Biotechnology Industry Organization (BIO) and as independent director of Clementia Pharmaceuticals (CMTA) acquired by IPSEN for $1.2B in 2019, Advanced Accelerator Applications (AAAP) acquired by Novartis for $3.9B in 2018, Baxalta (BXLT) acquired by Shire for $32B in 2016, Trevena (TRVN) and Noven (NOVN) acquired by Hisamitsu for $459M in 2009. Dr. Nader earned his French Doctorate in Medicine from St. Joseph University (Lebanon) and his Physician Executive MBA from the University of Tennessee.